The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
23773153 |
33 |
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design. |
Technical University of Dortmund |
22621397 |
39 |
Irreversible protein kinase inhibitors: balancing the benefits and risks. |
Covalution Pharma |
17850214 |
99 |
The selectivity of protein kinase inhibitors: a further update. |
University of Dundee |
11277536 |
130 |
7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src. |
Novartis Pharma Research |
11277535 |
80 |
7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src. |
Novartis Pharma Research |
27309760 |
96 |
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. |
University of Washington |
10866395 |
33 |
SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. |
Novartis Pharma |
10853665 |
104 |
Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. |
Novartis Pharma |
26914744 |
24 |
Chemical Space of DNA-Encoded Libraries. |
University of Utah |
9599227 |
57 |
Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. |
Warner-Lambert |
12921854 |
130 |
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. |
Harvard University |
10347254 |
11 |
Cloning and functional expression of the human histamine H3 receptor. |
R. W. Johnson Pharmaceutical Research Institute |
10340630 |
3 |
Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. |
Mcgill University |
18849971 |
56 |
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. |
University of California San Francisco |